MedPath

Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

Completed
Conditions
Non-Muscle Invasive Bladder Urothelial Carcinoma
Non Muscle Invasive Bladder Cancer
Registration Number
NCT06020807
Lead Sponsor
Nucleix Ltd.
Brief Summary

This is a prospective study to establish the analytical specificity of Bladder EpiCheck test in urine samples from healthy population and urology patients without prior history or evidence of bladder cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
168
Inclusion Criteria
  • Age 22 or older

  • Able to sign the informed consent form

  • Normal, healthy subjects or subjects with one of the following conditions:

    1. Benign non-genitourinary disease (e.g. heart disease)
    2. Non-genitourinary cancers (e.g. lung, CRC, breast)
    3. Genitourinary disease other than bladder cancer including:
    4. Benign prostatic hyperplasia (BPH)
    5. Microhematuria proven negative for bladder cancer through prior UCC evaluation
    6. Inflammation/infection
    7. Symptomatic sexually transmitted disease (STD)
    8. Urinary tract stones
    9. Genitourinary trauma
  • Subjects with native bladder

Exclusion Criteria
  • Known current or prior diagnosis of bladder cancer (non-muscle or muscle invasive)
  • Currently in work-up due to suspicion of cancer of any kind

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
SpecificityDay 1

The primary endpoint of the study is the specificity of the Bladder EpiCheck Test in healthy population.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Urology San Antonio

🇺🇸

San Antonio, Texas, United States

Urology San Antonio
🇺🇸San Antonio, Texas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.